DBPR108 is primarily investigated for its potential therapeutic applications in the treatment of various diseases, particularly in the field of oncology. It has shown promise as a selective inhibitor targeting specific signaling pathways involved in cancer cell proliferation and survival. Research suggests its efficacy in inhibiting tumor growth in preclinical models, making it a candidate for further development as an anti-cancer agent. Additionally, it is being studied for its role in modulating immune responses, which could enhance its utility in combination therapies with immunotherapies. Its application extends to exploring its effects on other diseases where dysregulated signaling pathways play a critical role, such as inflammatory and autoimmune conditions. Ongoing studies aim to optimize its pharmacological properties and evaluate its safety and efficacy in clinical trials.